Viral Safety Approaches For Advanced Therapy Medicinal Products
Source: Parenteral Drug Association (PDA)
By Thomas R. Kreil, Ph.D., Shire
The availability of plasma-derived medicinal products— one of the earliest achievements of medical biotechnology—has enabled great progress in the treatment of specialized conditions such as hemophilia and immune deficiencies. Yet early on, the biologic materials used to develop these products were also found to be vulnerable to infectious disease agents. Today, manufacturers safeguard these products during the development process through a set of measures commonly referred to as the “Safety Tripod.”
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Parenteral Drug Association (PDA)
This website uses cookies to ensure you get the best experience on our website. Learn more